Amana Care Clinic – Muscatine has announced enhanced focus on walk-in medical services to address increased seasonal healthcare demands in the Muscatine community, as respiratory illnesses and ...

Regulatory clearance of Bentrio in allergic rhinitis for Mainland ChinaNearly 200 million Chinese estimated to suffer from allergic rhinitisBentrio to be launched by partner Nuance Pharma HAMILTON, ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely ...

The company said additional testing of its nasal sprays found yeast, mold and bacterial contamination, prompting a voluntary ...

Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending ...

Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. "Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment," at 4:21 p.m. ET, ...

Cardamyst is now FDA approved as a self-administered intranasal treatment for acute episodes of paroxysmal supraventricular tachycardia.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market ...

Milestone Pharmaceuticals (MIST) announced that the U.S. Food and Drug Administration, FDA, approved its first commercial product, CARDAMYST nasal ...

The US FDA has approved etripamil (Cardamyst) nasal spray for the self-administered treatment of acute symptomatic paroxysmal ...